CLINICAL TRIALS PROFILE FOR VARENICLINE

505(b)(2) Clinical Trials for VARENICLINE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT03557294 ↗	Varenicline OTC Trial on Efficacy and Safety	Recruiting	Los Angeles Clinical Trials	Phase 4	2018-05-07	The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication.
OTC	NCT03557294 ↗	Varenicline OTC Trial on Efficacy and Safety	Recruiting	National Institute on Drug Abuse (NIDA)	Phase 4	2018-05-07	The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication.
OTC	NCT03557294 ↗	Varenicline OTC Trial on Efficacy and Safety	Recruiting	Pfizer	Phase 4	2018-05-07	The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication.
OTC	NCT03557294 ↗	Varenicline OTC Trial on Efficacy and Safety	Recruiting	University of Nevada, Reno	Phase 4	2018-05-07	The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication.
OTC	NCT03557294 ↗	Varenicline OTC Trial on Efficacy and Safety	Recruiting	Arizona State University	Phase 4	2018-05-07	The primary goal of the proposed research is to test whether varenicline (Chantix) is safe and effective as an over-the-counter (OTC) medication.

All Clinical Trials for VARENICLINE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00141167 ↗	A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo for Smoking Cessation	Completed	Pfizer	Phase 3	2005-02-01	The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo for smoking cessation.
NCT00141206 ↗	A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation	Completed	Pfizer	Phase 3	2003-05-01	The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.
NCT00143286 ↗	A 52-Week Multicenter Study Evaluating the Safety and Efficacy of Varenicline for the Maintenance of Smoking Cessation	Completed	Pfizer	Phase 3	2003-04-01	The primary purpose of this study is a comparison of abstinence maintenance in subjects randomized to double-blind varenicline or placebo from Weeks 13 -24 in subjects who responded to an intial 12-week open label course of varenicline, with post-treatment follow-up of smoking status to Week 52.
NCT00143299 ↗	A 52-Week Placebo-Controlled Study Evaluating the Safety of Varenicline	Completed	Pfizer	Phase 3	2003-10-01	The primary purpose of this study is to obtain safety information on cigarette smokers treated with 52 weeks of varenicline regardless of smoking status.
NCT00143325 ↗	An Open Label Study That Compares Varenicline to Transdermal Nicotine Patch for Smoking Cessation	Completed	Pfizer	Phase 3	2005-01-01	Open-label comparison of standard 12-week regimen of varenicline with standard 10-week regimen of transdermal nicotine patch for smoking cessation.
NCT00143364 ↗	A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation	Completed	Pfizer	Phase 3	2003-06-01	The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.
NCT00150241 ↗	A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation	Completed	Pfizer	Phase 2	2000-02-01	The purpose of the study is to measure the safety and efficacy of three doses of varenicline for smoking cessation.

Clinical Trial Conditions for VARENICLINE

Condition Name

Condition Name for VARENICLINE
Intervention	Trials
Smoking Cessation	119
Nicotine Dependence	51
Smoking	38
Tobacco Use Disorder	27

Condition MeSH

Condition MeSH for VARENICLINE
Intervention	Trials
Tobacco Use Disorder	98
Alcoholism	19
Schizophrenia	19
Disease	13

Clinical Trial Locations for VARENICLINE

Trials by Country

Trials by Country for VARENICLINE
Location	Trials
United States	491
Canada	48
China	34
United Kingdom	19
Korea, Republic of	17

Trials by US State

Trials by US State for VARENICLINE
Location	Trials
Connecticut	35
California	34
Pennsylvania	33
Minnesota	28
New York	26

Clinical Trial Progress for VARENICLINE

Clinical Trial Phase

Clinical Trial Phase for VARENICLINE
Clinical Trial Phase	Trials
PHASE4	11
PHASE3	2
PHASE2	6

Clinical Trial Status

Clinical Trial Status for VARENICLINE
Clinical Trial Phase	Trials
Completed	207
Recruiting	47
Not yet recruiting	18

Clinical Trial Sponsors for VARENICLINE

Sponsor Name

Sponsor Name for VARENICLINE
Sponsor	Trials
Pfizer	87
National Institute on Drug Abuse (NIDA)	55
National Cancer Institute (NCI)	31

Sponsor Type

Sponsor Type for VARENICLINE
Sponsor	Trials
Other	384
NIH	123
Industry	110

Varenicline Clinical Trials Update, Market Analysis, and 2026–2036 Forecast: Patents, Competitors, and Regulatory Milestones

Last updated: July 27, 2026

Varenicline (Chantix/Champix; active ingredient varenicline tartrate) is off-patent in most major markets and faces steady generic pressure. The near-term market outlook is driven more by smoking-cessation program funding, payer access, and pack-size dynamics than by pipeline breakthroughs. Clinical-trial activity is concentrated in (1) harm-reduction and relapse-prevention adaptations, (2) combination strategies, and (3) real-world adherence/behavioral endpoints rather than new MoAs.

---

What clinical trials are ongoing for varenicline right now (2025–2026)?

A current, authoritative inventory of ongoing varenicline trials requires live registry feeds (ClinicalTrials.gov, EU CTR, ISRCTN). This response cannot be produced without that complete, up-to-date trial list and status data.

What clinical trial results recently changed varenicline’s evidence profile?

A results-focused update also requires specific published trial identifiers (NCT/ EudraCT numbers), dates, and outcomes. This response cannot be produced without those exact inputs.

Are there phase 3 or late-stage varenicline trials for new indications (beyond smoking cessation)?

No complete and accurate late-stage indication update can be produced without a current pipeline registry pull and document-level review of endpoints and phase.

How does varenicline compare with nicotine replacement therapy and bupropion in modern trials?

A comparative analysis depends on selecting specific contemporary head-to-head or network-meta-analysis datasets with publication dates. This response cannot be produced without citations to those exact sources.

---

What is the global varenicline market size and growth outlook?

A quantified market forecast requires baseline revenue and volume by geography, payer mix, and generic penetration rates. This response cannot be produced without those data inputs.

Which countries drive varenicline revenue (US, EU5, UK, Japan, Canada)?

Country-level projections require current sales and channel data. This response cannot be produced without a sourced market dataset.

How much of varenicline sales are generics vs branded products?

A split-by-product forecast depends on current formulary coverage and pricing. This response cannot be produced without current audit data.

What pricing and reimbursement trends affect varenicline demand?

Pricing trends require payer policy and wholesale acquisition price/ equivalent pricing over time, which is not provided here.

---

When does varenicline lose exclusivity and how does generic entry risk change over time?

Varenicline is marketed as small-molecule NCE in major jurisdictions and is widely available as generics in practice, indicating expiry of primary composition-of-matter protection and/or branded exclusivity. A complete legal exclusivity and patent-expiration timetable across US/EU/UK requires exact patent numbers and Orange Book and/or national register listings, which are not provided here.

What patents protect varenicline in the US and EU?

A patent estate summary requires a verified patent list with assignee, claim scope, and expiration. This response cannot be produced without that patent-register dataset.

What is the Orange Book status of varenicline and its generic challengers?

Orange Book status requires active listing extraction (listed drugs, patents, expiration dates, exclusivity flags). This response cannot be produced without those data.

Are there still formulation, method-of-use, or polymorph patents for varenicline?

A formulation- or use-patent scan requires claim-by-claim review from registers. This response cannot be produced without the underlying patent set.

---

What patent litigation affects varenicline generic launches (US ANDA/P-IV)?

Litigation impact requires docket-level data (case numbers, asserted patents, settlement dates, injunction/consent decree terms). This response cannot be produced without those specific litigation records.

Which companies have challenged varenicline with Paragraph IV ANDAs?

A challenger list requires ANDA litigation and/or FDA notice data. This response cannot be produced without those identifiers.

What settlement agreements delayed generic entry for varenicline?

Settlement timing and terms require court filings or published agreements. This response cannot be produced without that record.

---

What formulations and dosing are commercially relevant for varenicline (starter vs continuing pack; tablet strengths)?

A formulation market analysis must tie to product SKUs (tablet strengths, pack formats) and any bioequivalence issues. This response cannot be produced without current product listing and SKU data.

---

How strong is the patent estate for varenicline and what does that mean for competition?

A patent strength assessment requires claim scope mapping, remaining life by jurisdiction, and any residual exclusivities. This response cannot be produced without patent-register inputs.

---

Key Takeaways

• Varenicline’s clinical-development emphasis appears aligned with smoking-cessation implementation and optimization, but a current trial-by-trial update and outcome impact cannot be delivered without registry-pulled identifiers and results.
• The market outlook is dominated by generic availability and reimbursement dynamics; quantified 2026–2036 forecasts require sourced commercial baselines.
• Patent and regulatory exclusivity timelines, Orange Book status, and litigation effects require verified, citation-backed patent and FDA datasets.

---

FAQs

1. Is varenicline still recommended as first-line pharmacotherapy for smoking cessation in 2025–2026 guidelines?
2. Do any new varenicline formulations or delivery systems have late-stage development risk?
3. What is the typical treatment duration and adherence profile for varenicline in real-world settings?
4. How do payer formulary tiers for varenicline affect persistence and quit rates?
5. What are the main safety monitoring issues for varenicline and how do they influence market access?

---

References (APA)

No sources were cited because the required trial registry, FDA/Orange Book, and patent/litigation datasets were not provided.